The Cooper Companies, Inc.

The Cooper Companies, Inc.

COONYSE / NASDAQHealthcareLarge cap

$58.88-$1.45 (-2.4%)

Last close · Data as of Nov 20, 2026

Market cap
$12.1B
P/E
32.3x
EV / EBITDA
13.9x
Revenue
$4.1B
Net margin
9.2%
ROCE
6.1%

-17.2% over the last year

The Cooper Companies, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.4%
3M
-22.7%
6M
-4.6%
1Y
-17.2%
5Y
-41.9%

52-week range

Day change -$1.45 (-2.4%) from $60 to $59 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in COO, bought on each weekday since 2021.

News & filings

What The Cooper Companies filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity of 4.6% against a peer median of 13.2%.

Strengths (1)

  • Operating margin of 16.7% against a peer median of 14.6%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia.

Read moreShow less

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Sector
Healthcare
Shares outstanding
195.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$12.1B
P/E
32.3x
P/B
1.5x
EV / EBITDA
13.9x
EV / Sales
3.5x
P/S
3.0x
52-week high
$84.32
52-week low
$53.27

Profitability

Operating margin
16.7%
Net margin
9.2%
EBITDA margin
25.5%
ROE
4.6%
ROCE
6.1%
ROA
3.0%
Asset turnover
0.33

Growth

Revenue
$4.1B
Revenue growth, 1Y
5.1%
Revenue CAGR, 3Y
7.3%
Net profit growth, 1Y
-4.4%
Free cash flow
$433.7M

Solvency

Current ratio
1.89
Debt / Equity
0.30
Debt / Assets
0.20
CFO / Net profit
2.12
Cash / Market cap
0.9%

Where the revenue went

Of every $100 of FY2025 revenue, $9 was left as net income.

The Cooper Companies, Inc. income statement flow, FY2025
The Cooper Companies, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.4B
RevenueGross profit$2.7B
Gross profitResearch and development$172.2M
Gross profitSelling, general and administrative$1.6B
Gross profitOther operating expenses$199.2M
Gross profitOperating income$682.9M
Operating incomePretax income$566.5M
Operating incomeInterest and other expense$116.4M
Pretax incomeTax and other$191.6M
Pretax incomeNet income$374.9M

Revenue and net profit

Revenue grew 5.1% in FY2025; net profit is the dashed line.

The Cooper Companies, Inc. revenue and net profit by fiscal year
The Cooper Companies, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.3B$385.8M
FY2023$3.6B$294.2M
FY2024$3.9B$392.3M
FY2025$4.1B$374.9M

Cash flows

FY2025: $796.1M from operations, $433.7M free after investment (dashed).

The Cooper Companies, Inc. operating and free cash flow by fiscal year
The Cooper Companies, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$692.4M$450.4M
FY2023$607.5M$215.0M
FY2024$709.3M$288.1M
FY2025$796.1M$433.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.1B+5.1%1Y
EBITDA
$1.0B-2.6%1Y
Net profit
$374.9M-4.4%1Y
Cash from operations
$796.1M+12.2%1Y
Free cash flow
$433.7M+50.5%1Y
Revenue CAGR, 3Y
7.3%
Net profit CAGR, 3Y
-1.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.1B$1.0B$374.9M$433.7M4.6%+5.1%-4.4%

Monthly returns

Month-by-month returns of COO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$12.4B
Liabilities$4.2B
Equity$8.2B
Paid-in capital$2.0B
Retained earnings$7.6B
Treasury stock$995.2M
Minority interest$200.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; COO highlighted.

P/E against peers

COO trades at 32.3x earnings against a peer median of 16.5x (a 95% premium).

Not shown (no positive earnings and no EV / Sales): Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
The Cooper Companies, Inc.COOthis companyP/E ↑ premium$12.1B32.3x1.5x4.6%13.9x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Zimmer Biomet Holdings, Inc.ZBH$16.8B23.8x1.3x5.6%10.7x
Solventum CorporationSOLV$14.3B9.2x2.8x30.8%7.2x
DaVita Inc.DVA$12.3B16.5x-18.9x-114.7%9.3x
Align Technology, Inc.ALGN$12.1B29.4x3.0x10.1%13.5x
Insulet CorporationPODD$10.1B41.0x6.7x16.3%21.2x
Universal Health Services, Inc.UHS$8.6B5.8x1.2x20.5%5.0x
Peer median—16.5x2.1x13.2%9.8x

Year-to-date ROI

COO since 1 January, against earlier years.

Historical volatility

COO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

The Cooper Companies, Inc. operating margin by fiscal year
The Cooper Companies, Inc. operating margin by fiscal year
DateOperating margin
FY202215.3%
FY202314.8%
FY202418.1%
FY202516.7%
LineFY2025
Cost of revenueCost Of Revenue$1.4B
Gross profitGross Profit$2.7B
Operating expensesOperating Expense$2.0B
Research and developmentResearch And Development$172.2M
Depreciation and amortisationDepreciation And Amortization In Income Statement$199.2M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$199.2M
Amortization$199.2M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$199.2M
Total expensesTotal Expenses$3.4B
Pretax incomePretax Income$566.5M

Learn while you research

Academy chapters picked for The Cooper Companies, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 32.3, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →